Cuffari S, Aiezza N, Antonelli A, Giani T, Rossolini G
J Antimicrob Chemother. 2024; 79(10):2724-2727.
PMID: 39087361
PMC: 11441996.
DOI: 10.1093/jac/dkae262.
Gong Y, Feng Y, Lv X
Microorganisms. 2024; 12(6).
PMID: 38930575
PMC: 11205768.
DOI: 10.3390/microorganisms12061193.
De la Cadena E, Mojica M, Rojas L, Castro B, Garcia-Betancur J, Marshall S
Microbiol Spectr. 2024; 12(6):e0410523.
PMID: 38700337
PMC: 11237465.
DOI: 10.1128/spectrum.04105-23.
Nordmann P, Bouvier M, Delaval A, Tinguely C, Poirel L, Sadek M
Emerg Infect Dis. 2024; 30(2):255-261.
PMID: 38270160
PMC: 10826745.
DOI: 10.3201/eid3002.221398.
Ding L, Shen S, Chen J, Tian Z, Shi Q, Han R
Clin Microbiol Rev. 2023; 36(4):e0000823.
PMID: 37937997
PMC: 10732083.
DOI: 10.1128/cmr.00008-23.
Clinical Characteristics and Outcome of Ceftazidime/Avibactam-Resistant Carbapenemase-Producing Infections: A Retrospective, Observational, 2-Center Clinical Study.
Oliva A, Campogiani L, Savelloni G, Vitale P, Lodi A, Sacco F
Open Forum Infect Dis. 2023; 10(7):ofad327.
PMID: 37476077
PMC: 10354859.
DOI: 10.1093/ofid/ofad327.
Laboratory automation, informatics, and artificial intelligence: current and future perspectives in clinical microbiology.
Mencacci A, De Socio G, Pirelli E, Bondi P, Cenci E
Front Cell Infect Microbiol. 2023; 13:1188684.
PMID: 37441239
PMC: 10333692.
DOI: 10.3389/fcimb.2023.1188684.
Resistance to Ceftazidime/Avibactam in KPC-Producing Isolates: A Real-Life Observational Study.
Campogiani L, Vitale P, Lodi A, Imeneo A, Fontana C, DAgostini C
Antibiotics (Basel). 2023; 12(5).
PMID: 37237722
PMC: 10215301.
DOI: 10.3390/antibiotics12050820.
Ceftazidime-Avibactam (C/A) Resistant, Meropenem Sensitive KPC-Producing in ICU Setting: We Are What We Are Treated with?.
Corcione S, De Benedetto I, Shbaklo N, Torsello G, Lupia T, Bianco G
Int J Mol Sci. 2023; 24(5).
PMID: 36902196
PMC: 10002972.
DOI: 10.3390/ijms24054767.
Treatment and diagnosis of severe KPC-producing infections: a perspective on what has changed over last decades.
Giacobbe D, Di Pilato V, Karaiskos I, Giani T, Marchese A, Rossolini G
Ann Med. 2023; 55(1):101-113.
PMID: 36856521
PMC: 9980017.
DOI: 10.1080/07853890.2022.2152484.
Outbreak of Klebsiella pneumoniae ST11 Resistant To Ceftazidime-Avibactam Producing KPC-31 and the Novel Variant KPC-115 during COVID-19 Pandemic in Argentina.
Nicola F, Cejas D, Gonzalez-Espinosa F, Relloso S, Herrera F, Bonvehi P
Microbiol Spectr. 2022; 10(6):e0373322.
PMID: 36445147
PMC: 9769968.
DOI: 10.1128/spectrum.03733-22.
Klebsiella pneumoniae Carbapenemase Variants Resistant to Ceftazidime-Avibactam: an Evolutionary Overview.
Hobson C, Pierrat G, Tenaillon O, Bonacorsi S, Bercot B, Jaouen E
Antimicrob Agents Chemother. 2022; 66(9):e0044722.
PMID: 35980232
PMC: 9487638.
DOI: 10.1128/aac.00447-22.
Implementation of Chromatic Super CAZ/AVI medium for active surveillance of ceftazidime-avibactam resistance: preventing the loop from becoming a spiral.
Bianco G, Boattini M, Comini S, Leone A, Bondi A, Zaccaria T
Eur J Clin Microbiol Infect Dis. 2022; 41(9):1165-1171.
PMID: 35933457
PMC: 9362390.
DOI: 10.1007/s10096-022-04480-x.
Update of clinical application in ceftazidime-avibactam for multidrug-resistant Gram-negative bacteria infections.
Zhen S, Wang H, Feng S
Infection. 2022; 50(6):1409-1423.
PMID: 35781869
DOI: 10.1007/s15010-022-01876-x.
The Rapid Emergence of Ceftazidime-Avibactam Resistance Mediated by KPC Variants in Carbapenem-Resistant in Zhejiang Province, China.
Liu C, Wu Y, Huang L, Zhang Y, Sun Q, Lu J
Antibiotics (Basel). 2022; 11(6).
PMID: 35740138
PMC: 9219983.
DOI: 10.3390/antibiotics11060731.
An interventional quasi-experimental study to evaluate the impact of a rapid screening strategy in improving control of nosocomial extended-spectrum beta-lactamase-producing Enterobacterales and carbapenemase-producing organisms in critically ill....
Martischang R, Francois P, Cherkaoui A, Renzi G, Fankhauser C, Schrenzel J
Crit Care. 2022; 26(1):166.
PMID: 35672757
PMC: 9172611.
DOI: 10.1186/s13054-022-04027-8.
Resistance to Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam in Gram-Negative MDR Bacilli: Molecular Mechanisms and Susceptibility Testing.
Gaibani P, Giani T, Bovo F, Lombardo D, Amadesi S, Lazzarotto T
Antibiotics (Basel). 2022; 11(5).
PMID: 35625273
PMC: 9137602.
DOI: 10.3390/antibiotics11050628.
Identification of a KPC Variant Conferring Resistance to Ceftazidime-Avibactam from ST11 Carbapenem-Resistant Strains.
Wu Y, Yang X, Liu C, Zhang Y, Cheung Y, Chan E
Microbiol Spectr. 2022; 10(2):e0265521.
PMID: 35416703
PMC: 9045388.
DOI: 10.1128/spectrum.02655-21.
Impact of Ceftazidime-Avibactam Treatment in the Emergence of Novel KPC Variants in the ST307-Klebsiella pneumoniae High-Risk Clone and Consequences for Their Routine Detection.
Hernandez-Garcia M, Castillo-Polo J, Cordero D, Perez-Viso B, Garcia-Castillo M, Fuente J
J Clin Microbiol. 2022; 60(3):e0224521.
PMID: 35107303
PMC: 8925889.
DOI: 10.1128/jcm.02245-21.
Ceftazidime/Avibactam-Resistant subsp. Isolates in a Tertiary Italian Hospital: Identification of a New Mutation of the Carbapenemase Type 3 (KPC-3) Gene Conferring Ceftazidime/Avibactam Resistance.
Fontana C, Favaro M, Campogiani L, Malagnino V, Minelli S, Bossa M
Microorganisms. 2021; 9(11).
PMID: 34835481
PMC: 8624296.
DOI: 10.3390/microorganisms9112356.
